BACKGROUND: This study was undertaken to characterize the relation between the survival of patients with stage IIIB/IV nonsmall cell lung cancer (NSCLC) and pack-years of cigarette smoking (graded according to the American Joint Committee on Cancer staging system). METHODS: Data were analyzed from patients with stage IIIB/IV NSCLC who had completed a prospective smoking questionnaire. The impact of pack-years of cigarette smoking, age, sex, Karnofsky performance status (KPS), and the presence of weight loss >5% was evaluated on overall survival using univariate and multivariate analyses. RESULTS: Smoking history and clinical data were available for 2010 patients with stage IIIB/IV NSCLC (1004 women and 1006 men). Approximately 70% of patients (1409 patients) had smoked >15 pack-years, 13% (270) were former and current smokers who had smoked < or = 15 pack-years, and 16% (331) were never-smokers (<100 lifetime cigarettes). Never-smokers had a longer median survival compared with former or current smokers (17.8 months vs 11.3 months; log-rank P < .001). Among smokers, patients with a < or = 15 pack-year history of smoking had a longer median survival than patients who had smoked >15 pack-years (14.6 months vs 10.8 months; log-rank P = .03). As the number of pack-years increased, the median overall survival decreased (log-rank P < .001). Multivariate analysis indicated that a history of smoking was an independent prognostic factor (hazard ratio, 1.36; P < .001). CONCLUSIONS: More cigarette smoking, measured in pack-years, was associated with decreased survival after a diagnosis of stage IIIB/IV NSCLC. Trials assessing survival in patients with stage IIIB/IV NSCLC should report a detailed cigarette smoking history for all patients. Copyright 2009 American Cancer Society.
BACKGROUND: This study was undertaken to characterize the relation between the survival of patients with stage IIIB/IV nonsmall cell lung cancer (NSCLC) and pack-years of cigarette smoking (graded according to the American Joint Committee on Cancer staging system). METHODS: Data were analyzed from patients with stage IIIB/IV NSCLC who had completed a prospective smoking questionnaire. The impact of pack-years of cigarette smoking, age, sex, Karnofsky performance status (KPS), and the presence of weight loss >5% was evaluated on overall survival using univariate and multivariate analyses. RESULTS: Smoking history and clinical data were available for 2010 patients with stage IIIB/IV NSCLC (1004 women and 1006 men). Approximately 70% of patients (1409 patients) had smoked >15 pack-years, 13% (270) were former and current smokers who had smoked < or = 15 pack-years, and 16% (331) were never-smokers (<100 lifetime cigarettes). Never-smokers had a longer median survival compared with former or current smokers (17.8 months vs 11.3 months; log-rank P < .001). Among smokers, patients with a < or = 15 pack-year history of smoking had a longer median survival than patients who had smoked >15 pack-years (14.6 months vs 10.8 months; log-rank P = .03). As the number of pack-years increased, the median overall survival decreased (log-rank P < .001). Multivariate analysis indicated that a history of smoking was an independent prognostic factor (hazard ratio, 1.36; P < .001). CONCLUSIONS: More cigarette smoking, measured in pack-years, was associated with decreased survival after a diagnosis of stage IIIB/IV NSCLC. Trials assessing survival in patients with stage IIIB/IV NSCLC should report a detailed cigarette smoking history for all patients. Copyright 2009 American Cancer Society.
Authors: J P O'Connell; M G Kris; R J Gralla; S Groshen; A Trust; J J Fiore; D P Kelsen; R T Heelan; R B Golbey Journal: J Clin Oncol Date: 1986-11 Impact factor: 44.544
Authors: DuyKhanh Pham; Mark G Kris; Gregory J Riely; Inderpal S Sarkaria; Tiffani McDonough; Shaokun Chuai; Ennapadam S Venkatraman; Vincent A Miller; Marc Ladanyi; William Pao; Richard K Wilson; Bhuvanesh Singh; Valerie W Rusch Journal: J Clin Oncol Date: 2006-02-27 Impact factor: 44.544
Authors: T Fujisawa; T Iizasa; Y Saitoh; Y Sekine; S Motohashi; T Yasukawa; K Shibuya; K Hiroshima; H Ohwada Journal: J Clin Oncol Date: 1999-07 Impact factor: 44.544
Authors: J O Ebbert; B A Williams; Z Sun; M C Aubry; J A Wampfler; Y I Garces; R L Meyer; P Yang Journal: Lung Cancer Date: 2005-02 Impact factor: 5.705
Authors: Giorgio Vittorio Scagliotti; Purvish Parikh; Joachim von Pawel; Bonne Biesma; Johan Vansteenkiste; Christian Manegold; Piotr Serwatowski; Ulrich Gatzemeier; Raghunadharao Digumarti; Mauro Zukin; Jin S Lee; Anders Mellemgaard; Keunchil Park; Shehkar Patil; Janusz Rolski; Tuncay Goksel; Filippo de Marinis; Lorinda Simms; Katherine P Sugarman; David Gandara Journal: J Clin Oncol Date: 2008-05-27 Impact factor: 44.544
Authors: Vincent A Miller; Mark G Kris; Neelam Shah; Jyoti Patel; Christopher Azzoli; Jorge Gomez; Lee M Krug; William Pao; Naiyer Rizvi; Barbara Pizzo; Leslie Tyson; Ennapadam Venkatraman; Leah Ben-Porat; Natalie Memoli; Maureen Zakowski; Valerie Rusch; Robert T Heelan Journal: J Clin Oncol Date: 2004-03-15 Impact factor: 44.544
Authors: Mizuki Nishino; Stephanie Cardarella; Suzanne E Dahlberg; Tetsuro Araki; Christine Lydon; David M Jackman; Michael S Rabin; Hiroto Hatabu; Bruce E Johnson Journal: Eur J Radiol Date: 2015-02-07 Impact factor: 3.528
Authors: Travis J Meyers; Shen-Chih Chang; Po-Yin Chang; Hal Morgenstern; Donald P Tashkin; Jian-Yu Rao; Wendy Cozen; Thomas M Mack; Zuo-Feng Zhang Journal: Int J Cancer Date: 2017-02-22 Impact factor: 7.396
Authors: Melissa L Johnson; Camelia S Sima; Jamie Chaft; Paul K Paik; William Pao; Mark G Kris; Marc Ladanyi; Gregory J Riely Journal: Cancer Date: 2012-07-18 Impact factor: 6.860
Authors: Sandra P D'Angelo; M Catherine Pietanza; Melissa L Johnson; Gregory J Riely; Vincent A Miller; Camelia S Sima; Maureen F Zakowski; Valerie W Rusch; Marc Ladanyi; Mark G Kris Journal: J Clin Oncol Date: 2011-04-11 Impact factor: 44.544
Authors: Anna M Varghese; Camelia S Sima; Jamie E Chaft; Melissa L Johnson; Gregory J Riely; Marc Ladanyi; Mark G Kris Journal: J Thorac Oncol Date: 2013-01 Impact factor: 15.609